Figure 1 (A) Chest computed tomography scans of the patient

Slides:

Advertisements

Similar presentations

How to manage suspected cancer

Advertisements

From: An open day in the metric space

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Figure 1 WBC count (A), platelet count (B), MPV (C), platelet activation rate (D) and TGF-β1concentration (E) in the PF of women with endometriosis and.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

From: Global Banking: Recent Developments and Insights from Research*

Figure 2. Quality of life (QOL) scores for functional scale items

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 2. CONSORT flow diagram.

Figure 1 (A) Chest x-ray (posteroanterior view) showed a cavitary lesion with an air-fluid level in the right upper lobe. (B) Computed tomography of the.

Fig. 1 GBM TIMs expand to inhibit vaccine-induced T-cell mediated tumor cytolysis via PD-1/PD-L1 regulatory pathway. (A, D) CD163, DAPI, (B, E) PD-L1,

pSS: primary SS; Scl: scleroderma.

Figure 3. Examples of tweets classified as ridicule.

Figure 2: The Medical Imaging Projection System projecting the real-time fluorescent image on the surface of the lung during surgery (left). The cut surface.

Figure 1. Selection of papers.

Fig. 1 Flow chart of study selection

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. Kaplan–Meier survival analysis in patients

Fig 1 Respiratory support escalation strategies for study patients

Figure 1 Flow chart showing the selection of publications identified in the literature search. From: GnRH antagonist versus long agonist protocols in IVF:

From: Where do we go from here

From: A European Disease

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Example 14. Schubert, Quartet in G Major, D

Fig. 1 Flow diagram of patient selection and study design.

Figure 1. Suggested algorithm for locoregional lymph node staging in patients with non-metastatic NSCLC. CT, computed tomography; EBUS, endoscopic bronchial.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

From: Estimating the Location of World Wheat Price Discovery

Figure 1: Time points at which sperm samples were analysed for aneuploidy frequencies in controls and cancer patients From: Sperm aneuploidy frequencies.

Figure 1: Logistic regression showing association of prescribing provider and patient panel characteristics with occurrence of a hospitalization or ED.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.

Figure 1 Study flow chart

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

FIG. 4. Working lifetime combined risk from fatal heart disease and lung cancer based on Hong Kong exposure to secondhand tobacco smoke and both US and.

Figure 3. Changes from baseline in activated CD4+ T cells (% CD4+CD25+) during the 52-week intervention period in the.

Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia Hiroaki Tachi, MD, Toshihiro Shiozawa, MD, Chio Sakai, MD, Mariko Kasuga,

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

توزیع جغرافیایی مرگ به دلیل بدخیمی در کشور Age-standardized incidence rate of all cancers per 100 000 in female in Iran 2005–2006.

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Hironori Yoshida, MD, Young Hak Kim, MD Journal of Thoracic Oncology

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

Fig. 1 Flow chart of included patients for analyses

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived.

Figure 1. Radiographic and gross pathologic measurements of ‘tumor mass’ include areas of immune-mediated tumor ... Figure 1. Radiographic and gross pathologic.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. A summary of phase 3 trials for previously untreated advanced/metastatic NSCLC. AEs, adverse events; Beva, ... Figure 1. A summary of phase 3.

Figure 1. CONSORT diagram.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Presentation transcript:

Figure 1 (A) Chest computed tomography scans of the patient Figure 1 (A) Chest computed tomography scans of the patient. Flow cytometric analysis of lymphocyte subsets in the right pleural fluid of the patient. (B) Expression of CD19 and CD3 on CD45<sup>+</sup> cells. (C) Expression of CD4 and CD8 on CD3<sup>+</sup> T cells. Flow cytometric analysis of immune-checkpoint proteins expressed on the surface of T cells in pleural effusion of the patient and two cases of lung cancer. Expression of PD-1 and TIM-3 on CD8<sup>+</sup> T cells and CD4<sup>+</sup> T cells in pleural effusion was examined for the present patient (D) as well as for patients with lung cancer whose disease progressed during treatment with erlotinib (E) or osimertinib (F). From: Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment Ann Oncol. 2017;28(8):2038-2039. doi:10.1093/annonc/mdx214 Ann Oncol | © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.